|Izabela Sadowska-Woda, Edyta Bieszczad-Bedrejczuk|
Desloratadine (DCL), major metabolite of loratadine, is a new selective,
antihistaminic drug. DCL displays linear pharmacokinetics. Age
and sex have no apparent effect on this drug’s metabolism, and
food does not affect its bioavailability or absorption. DCL does not
significantly interact with cytochrome P450 inhibitors (e.g. macrolide
antibiotics and antifungal drugs from the azole derivatives group,
such as ketoconazole).
This article reviews and discusses antihistaminic and anti-inflammatory
properties of DCL. In the paper, special attention is given to the
antioxidative activity of DCL, confirmed both in vitro and in vivo.
Therefore, DCL may have a potential to effectively treat “free radical”
pathologies. The article also presents data about the efficacy of DCL
in the treatment of allergic rhinitis and spontaneous chronic urticaria.
On the basis of data from many studies, it could be concluded that
DCL may be used as a safe drug with positive clinical activity in the
above mentioned illnesses.
keywords: dezloratadyna, alergiczny nieżyt nosa, pokrzywka spontaniczna przewlekła, desloratadine, allergic rhinitis, spontaneous chronic urticaria
pages: from 189 to 196
|estimated time of download (244 kB)|